Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland. (25th October 2016)

• Record Type: Journal Article
• Authors: Waqas, Sarmad; O'Connor, Mairead; Levey, Ciara; Mallon, Paddy; Sheehan, Gerard; Patel, Anjali; Avramovic, Gordana; Lambert, John S
• Is Part Of: SAGE open medicine. Volume 4(2016)
• Publication Date: 2016-10-25
• Subjects: Pharmacoepidemiology/drug safety -- dolutegravir -- HIV -- viral load -- naive -- integrase inhibitor -- tolerability; Medicine -- Periodicals; 610.5
• DOI: 10.1177/2050312116675813
• Languages: English
• ISSNs: 2050-3121

Abstract

Objective: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. Methods: Retrospective health care record of 61 consecutive HIV treatment-naive patients started on dolutegravir was reviewed and analysed on SPSS. Results: The mean initial viral load was 160826.05 copies/mL (range, 79–1, 126, 617 copies/mL). HIV viral load became non-detectable in 63.9% of patients on dolutegravir within 3 months. In all, 60.7% of patients reported no side effects on dolutegravir; 98.4% of the patients claimed full compliance to their antiretrovirals. Conclusion: Dolutegravir was found to be efficacious and well tolerated in HIV-infected treatment-naive patients.